Most Recent
Pfizer calls out ‘impermissible fishing expedition’ in fight over Enbrel biosimilar
Drug giant Pfizer has blasted Samsung Bioepis' “fishing expedition” in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity.  
Qld tech firm denies using confidential info for battery patent applications
Queensland technology company Anteotech has hit back at a lawsuit claiming it misused Ferroglobe’s confidential silicon samples in a patent application after a failed collaboration, saying the global speciality metals producer acquiesced to the use. 
Novartis can’t have separate trial on blood pressure drug invalidity claim
Novartis has lost its bid to have Pharmacor’s claim that its patent for a blood pressure drug is invalid decided ahead of a main trial where the Swiss pharmaceutical giant will allege the generic drug maker is threatening to infringe its patent. 
Ferroglobe accuses ASX company of using confidential IP after failed collaboration
Ferroglobe has claimed a Queensland technology company used its confidential information in new patent applications, as the global specialty metals producer races to protect its IP before the applications are published.
‘Substantial industrial theft’: Hytera to face damages for stealing Motorola’s source code
A judge has found Shenzhen-based based radio manufacturer Hytera engaged in "substantial industrial theft" by appropriating Motorola's source code for its digital mobile radios and should be on the hook for additional damages for "flagrantly" infringing Motorola's copyright.
Novartis, Pharmacor resolve suit over Gilenya patents
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant's patents for blockbuster MS drug Gilenya.
Defamation, class action barristers among 20 new silks
Twenty barristers have risen to the ranks of senior counsel in New South Wales, including a veteran defamation barrister, two counsel with class action expertise and part of the team that saw ASIC's claims against two Rio Tinto executives dropped.
Full Court upholds validity of Pfizer’s Dynastat patent
A judge has thrown out competing appeals of a decision finding Pfizer's patent for its post-operative injectable painkiller Dynastat is valid and that Australian drug maker Juno Pharmaceuticals infringed the patent by selling generic versions of the drug in Australia.
Bangkok Broadcasting settles ‘7’ trade mark stoush with Seven Network
Bangkok Broadcasting and Seven Networks have settled two lawsuits over the Thai broadcaster's registration of '7' marks in Australia.